70 completed, 25 terminated, 17 unknown, 11 recruiting. 48 Phase 3, 43 Phase 2, 31 Phase 4, 17 Not applicable, 4 Phase 1.
Follow Corticosteroids: new trials by email Literature Review of Corticosteroids trials Research Report on Corticosteroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis Etrasimod, Placebo, Corticosteroids - Immune Checkpoint Inhibitor-Related Diarrhea and Colitis | Phase 2 | Withdrawn | Yale University | 2026-01-01 | 2026-01-14 | |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy Conventional Therapy, Telitacicept - Refractory Chronic Inflammatory Demyelinating Polyneuropathy | Not applicable | Active not recruiting | Sichuan Academy of Medical Sciences | 76 | 2025-09-26 | 2026-05-19 |
| Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases Bevacizumab, Dexamethasone - Radiation Necrosis, High Grade Glioma (III or IV) | Phase 3 | Recruiting | The Netherlands Cancer Institute | 408 | 2025-06-19 | 2026-07-13 |
| Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) Ruxolitinib, Corticosteroids - GVHD,Acute, Stem Cell Transplant Complications | Phase 2 | Recruiting | Daihong Liu | 168 | 2025-06-01 | 2026-01-14 |
| Impact of Lung Boost Device on Ventilatory Functions and Fatigue in Patients With Interstitial Lung Diseases Lung Boost Device Training, Traditional physical therapy program, Medical Treatment - Interstitial Lung Disease | Not applicable | Completed | Cairo University | 40 | 2025-05-29 | 2025-09-09 |
| Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases Bevacizumab, Placebo, Prednisolone - Radionecrosis of Brain, Brain Metastases | Phase 3 | Recruiting | Institut Cancerologie de l'Ouest | 84 | 2025-04-29 | 2025-08-17 |
| Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia Exosomes, PRP, Corticosteroids - Postherpetic Neuralgia ( PHN ) | Not applicable | Recruiting | Zagazig University | 45 | 2025-02-02 | 2026-05-04 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease INCA034176, Placebo, Corticosteroids - Chronic Graft-versus-host-disease | Phase 3 | Recruiting | Incyte Corporation | 240 | 2025-01-21 | 2026-10-09 |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Axatilimab, Ruxolitinib, Corticosteroids - Chronic Graft-versus-host-disease | Phase 2 | Active not recruiting | Incyte Corporation | 130 | 2024-10-11 | 2026-10-15 |
| Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis Any treatments regimen - Granulomatous Mastitis, Mastitis Chronic | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 320 | 2024-08-28 | 2026-10-15 | |
| A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids - Graft Versus Host Disease, Acute | Phase 2 | Terminated | Cynata Therapeutics Limited | 65 | 2024-03-04 | 2026-10-22 |
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura eltrombopag and romiplastim - ITP - Immune Thrombocytopenia | Not yet recruiting | Assiut University | 100 | 2023-12-01 | 2023-11-18 | |
| Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital corticosteroids - Bronchial Asthma | Unknown | Sohag University | 200 | 2023-11-01 | 2023-11-21 | |
| Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 10 | 2023-06-05 | 2026-03-24 |
| The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia Corticosteroids, Corticosteroids and Ruxolitinib - Severe Checkpoint Inhibitor Pneumonitis | Not applicable | Completed | Peking Union Medical College Hospital | 60 | 2023-04-14 | 2026-07-28 |
| Topical Sulfasalazine and Oral Lichen Planus sulfasalazine 500 MG, corticosteroids - Oral Lichen Planus, Topical Sulfasalazine | Phase 3 | Unknown | Cairo University | 46 | 2023-03-01 | 2024-08-01 |
Showing 20 of 139. Sign in to see all of them.
Graft vs Host Disease (6) · Lupus Nephritis (5) · Asthma (4) · Kidney Failure, Chronic (4) · Lupus Erythematosus, Systemic (4) · Arthritis, Rheumatoid (3) · Brain Neoplasms (3) · Bronchiolitis Obliterans Syndrome (3) · Leprosy (3) · Purpura, Thrombotic Thrombocytopenic (3) · Rejection, Psychology (3) · Anosmia (2) · Autoimmune Diseases (2) · Colitis (2) · Colitis, Ulcerative (2)
Novartis Pharmaceuticals (17) · Hoffmann-La Roche (10) · Astellas Pharma Inc (6) · Genentech, Inc. (5) · Novartis (5) · Cairo University (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Bristol-Myers Squibb (3) · Incyte Corporation (3) · London School of Hygiene and Tropical Medicine (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · ITB-Med LLC (2) · Icahn School of Medicine at Mount Sinai (2) · Kyntra Bio (2) · Medical University of South Carolina (2)
United States (57) · France (28) · Germany (26) · Italy (24) · Spain (23) · Belgium (18) · Canada (18) · China (18) · United Kingdom (18) · Norway (16) · Sweden (16) · Czechia (15) · Australia (14) · Netherlands (14) · Poland (12)
Abraham Shaked, MD, PhD (1) · Ahmed M Abdul Ghani, MD (1) · Aiming Yang, M.D. (1) · Albert Assad, MD (1) · Aliaa A Bedeir, BDS (1) · Amit Dagan, Dr. (1) · Ann Traynor, MD (1) · Averell Sherker, MD (1)
PMID 12176626, PMID 12176628, PMID 15233820, PMID 18050221, PMID 18490588, PMID 21334736, PMID 21536936, PMID 22257543, PMID 22325903, PMID 22471345, PMID 22891232, PMID 22946986, PMID 23230975, PMID 23252525, PMID 23422495, PMID 23471469, PMID 23656665, PMID 23714399, PMID 24604142, PMID 24794368, PMID 25041227, PMID 25070687, PMID 25419594, PMID 25504861, PMID 25873064, PMID 26151607, PMID 26338095, PMID 26369526, PMID 26472752, PMID 26725209, PMID 26820618, PMID 26888217, PMID 27220348, PMID 27547871, PMID 27723281, PMID 28230646, PMID 28745999, PMID 28817434, PMID 28864814, PMID 29045736, PMID 29149958, PMID 29507942, PMID 29519540, PMID 29752413, PMID 29954336, PMID 30211826, PMID 30231851, PMID 30244988, PMID 30312541, PMID 30354362
2009 (4), 2008 (2), 2015 (2), 2023 (2), 2005 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1), U01DC003209 (1), U01DK062456 (1), U01HL072268 (1)